Related references
Note: Only part of the references are listed.Novel immunotherapies in lymphoid malignancies
Connie Lee Batlevi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan
Takashi Taga et al.
PEDIATRIC BLOOD & CANCER (2016)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2015)
Motor, linguistic, personal and social aspects of children with Down syndrome
Amanda Tragueta Ferreifta-Vasques et al.
JOURNAL OF APPLIED ORAL SCIENCE (2015)
DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3
Benjamin J. Thompson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications
Ramzi Abbassi et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Refractive error, binocular vision and accommodation of children with Down syndrome
Tanisha Watt et al.
CLINICAL AND EXPERIMENTAL OPTOMETRY (2015)
Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia and Down Syndrome
Hiroaki Goto et al.
PEDIATRIC BLOOD & CANCER (2015)
A case of B-cell acute lymphoblastic leukemia in a child with Down syndrome bearing a t(2;12)(p12;p13) involving ETV6 and biallelic IGH@ rearrangements
Carlos A. Tirado et al.
BIOMARKER RESEARCH (2015)
Novel agents for the treatment of childhood acute leukemia
Colleen E. Annesley et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2015)
A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms
Raajit Rampal et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
The molecular regulation of Janus kinase (JAK) activation
Jeffrey J. Babon et al.
BIOCHEMICAL JOURNAL (2014)
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group
Trudy D. Buitenkamp et al.
BLOOD (2014)
Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol
Katharine Patrick et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
The Down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1 and Cyclin D1 and induces cell cycle exit and neuronal differentiation
Ulf Soppa et al.
CELL CYCLE (2014)
Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries
Catarina Lundin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia
Yilong Li et al.
NATURE (2014)
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation
Andrew A. Lane et al.
NATURE GENETICS (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Outcome of Transplantation for Acute Lymphoblastic Leukemia in Children With Down Syndrome
Johann K. Hitzler et al.
PEDIATRIC BLOOD & CANCER (2014)
DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease
M. J. Barallobre et al.
CELL DEATH & DISEASE (2014)
Prognosis and management of acute myeloid leukemia in patients with Down syndrome
J. Timothy Caldwell et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
The genomic landscape of acute lymphoblastic leukemia in children and young adults
Charles G. Mullighan
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
Dosage of Dyrk1a Shifts Cells within a p21-Cyclin D1 Signaling Map to Control the Decision to Enter the Cell Cycle
Jia-Yun Chen et al.
MOLECULAR CELL (2013)
Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia
C. Bohnstedt et al.
LEUKEMIA (2013)
IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan
Daisuke Asai et al.
CANCER MEDICINE (2013)
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
Ursula Creutzig et al.
BLOOD (2012)
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2012)
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2012)
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome
Sebastien Malinge et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Acute leukemias in children with Down syndrome
Laura Seewald et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations
T. D. Buitenkamp et al.
LEUKEMIA (2012)
Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A
Shaohong Ding et al.
NEUROBIOLOGY OF AGING (2012)
Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21
Anindita Roy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia
Vikki Rand et al.
BLOOD (2011)
Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling
Barbara Haemmerle et al.
DEVELOPMENT (2011)
DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly
Larisa Litovchick et al.
GENES & DEVELOPMENT (2011)
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias
Chen Shochat et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles
M. G. Loudin et al.
LEUKEMIA (2011)
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
Libi Hertzberg et al.
BLOOD (2010)
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group
Kelly W. Maloney et al.
BLOOD (2010)
CRLF2 and JAK2 in B-Progenitor Acute Lymphoblastic Leukemia: A Novel Association in Oncogenesis
J. Devon Roll et al.
CANCER RESEARCH (2010)
Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia
Trudy D. Buitenkamp et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia
Akinori Yoda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia
Lyndal Kearney et al.
BLOOD (2009)
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia
Lisa J. Russell et al.
BLOOD (2009)
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia
Amos Gaikwad et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1
Kwan-Hyuck Baek et al.
NATURE (2009)
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia
Charles G. Mullighan et al.
NATURE GENETICS (2009)
Down syndrome: a cardiovascular perspective
J. C. Vis et al.
JOURNAL OF INTELLECTUAL DISABILITY RESEARCH (2009)
Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome
Gina Kirsammer et al.
BLOOD (2008)
Acute lymphoblastic leukemia and Down syndrome - Presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)
Maurizio Arico et al.
CANCER (2008)
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
Dani Bercovich et al.
LANCET (2008)
Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)
Anthony V. Moorman et al.
BLOOD (2007)
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia
Sebastien Malinge et al.
BLOOD (2007)
Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study
JA Whitlock et al.
BLOOD (2005)
Chromosomal protein HMGN1 enhances the acetylation of lysine 14 in histone H3
JH Lim et al.
EMBO JOURNAL (2005)
Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts
C Langebrake et al.
KLINISCHE PADIATRIE (2005)
Acute leukaemia in children with Down syndrome: a population-based Nordic study
B Zeller et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia
YB Ge et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Epidemiology of leukemia in children with Down syndrome
JA Ross et al.
PEDIATRIC BLOOD & CANCER (2005)
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome
J Wechsler et al.
NATURE GENETICS (2002)
Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study
QH Yang et al.
LANCET (2002)
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome
CM Zwaan et al.
BLOOD (2002)
Risks of leukaemia and solid tumours in individuals with Down's syndrome
H Hasle et al.
LANCET (2000)
The management of neoplastic disorders of haematopoiesis in children with Down's syndrome
B Lange
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
